With over 20 years of DMPK and clinical pharmacology experience in big pharma, biotech and at FDA, George brings a unique combination of drug development expertise and regulatory insight in clinical pharmacology to A2-Ai. He is a member of AAPS, AACR, and ASCPT, has co-authored over 20 peer-reviewed articles. As SVP of Clin Pharm, George emphasizes data-driven development decisions and optimal development strategies while working with clients to advance drug development.